Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, is pleased to announce the appointment of Sheryl Caswell as Head of Clinical Development.
Sheryl joins Medherant as the Company prepares to start clinical studies with its first product, an ibuprofen patch developed using its TEPI Patch technology.
Nigel Davis, CEO, commented, “We’re delighted that Sheryl will be joining us at such an important time in the Company’s development. Sheryl has over 20 years’ experience leading clinical development programmes on a wide range of products including other ibuprofen products”.
Medherant’s next-generation drug delivery platform, TEPI Patch, is designed to address many of the disadvantages of previous transdermal drug delivery patches.
It will enable a wider range of drugs to be delivered through the skin, including those that are unsuitable for oral administration, and improve the user experience.
Medherant is initially using the technology to develop products for pain relief, the first of which will be an ibuprofen patch. The technology will enable controlled release of drugs for up to at least 24 hours.
Sheryl commented: “I am delighted to join Medherant to lead clinical development at this exciting time and look forward to initiation of the Company’s first clinical study. I believe the TEPI Patch technology developed by Medherant will provide patients with a much-needed convenient dosing form for a wide range of drugs.”
Nicola Broughton, Head of Universities at Mercia Technologies PLC, which invested in Medherant last year, said, “Sheryl will be a great asset to the Medherant team, bringing a wealth of experience as the Company takes its next important step into clinical development. The technology is incredibly versatile and we are excited about Medherant developing a range of products to deliver drugs through the skin.”